Q-omics provides the consensus-scored POM121 profile across patient tissues and cancer cell-line models. POM121 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, POM121 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, POM121 RNA expression shows 19,860 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, HNSC, and THYM as cancer lineages where POM121 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POM121 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POM121 survival associations across molecular data types. POM121 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POM121 RNA expression–survival associations across cancer types. High POM121 expression shows unfavorable associations in LGG, CESC, MESO, THCA and COAD, but favorable associations in UCS. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for POM121 RNA expression.
This table summarizes POM121 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for POM121. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POM121 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRP, COAD, STAD and CHOL. The HNSC box plot shows higher POM121 RNA expression in tumor versus normal tissue (log2 FC = +0.992, t-test p < 0.001).
This table shows molecular features associated with POM121 in patient tissues and cancer cell lines. In patient samples, POM121 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, POM121 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
